This article has been retracted.
- Renin-angiotensin system (RAS) inhibitor use in patients with cardiovascular (CV) disease and hospitalized with COVID-19 was not associated with mortality risk in this large international study.
- Use of angiotensin-converting enzyme inhibitors (ACEis) was tied to a greater likelihood of discharge, but use of angiotensin receptor blockers (ARBs) was not.
Why this matters
- Editorial: these and other findings provide further support for continuing RAS inhibitor therapy in patients with COVID-19.
- 8910 patients, 169 hospitals.
- Mean age: 49 years; 40.0% women.
- Mean length of stay: 10.7±2.7 days.
- Overall hospital mortality: 5.8% (n=515).
- On multivariable analysis, in-hospital death was associated with (ORs; 95% CIs):
- Age >65 years: 1.93 (1.60-2.41).
- Coronary artery disease: 2.70 (2.08-3.51).
- Congestive heart failure: 2.48 (1.62-3.79).
- Cardiac arrhythmia: 1.95 (1.33-2.86).
- COPD: 2.96 (2.00-4.40).
- Current smoking: 1.79 (1.29-2.47).
- Immunosuppression, race/ethnicity, hyperlipidemia, and diabetes were not independently predictive of hospital death.
- Discharge odds (ORs; 95% CIs) were increased with:
- Female sex: 0.79 (0.65-0.95);
- Statin use: 0.35 (0.24-0.52); and
- ACEis: 0.33 (0.20-0.54).
- However, use of ARBs was not significantly associated: 1.23 (0.87-1.74).
- Multinational, multicenter, retrospective analysis of associations of CV disease and related drug therapies with COVID-19 mortality among hospitalized patients.
- Funding: None disclosed.
- Unidentified confounders.
- Primary hypothesis lacking.